Metir PLC - Product Development and Commercial Update
4 August 2026
Metir plc
("Metir", the "Group" or the "Company")
Product Development and Commercial Update
Microtox® LX commercial momentum builds, MechLine-
Metir plc (AIM: MET), the global provider of fast-response, mobile and point-of-use water and environmental monitoring technologies, is pleased to provide an update on commercial and product development progress across its product portfolio as the Company continues to execute its strategy of growing and building multiple recurring revenue streams.
Highlights
· Production of Microtox® LX instruments continues to increase, enabling supply from stock and trials with key new customers.
· During 2026, 144 customer quotations were issued, including 83 quotations for Microtox® LX and FX instruments, with 19 Microtox® LX systems sold year-to-date.
· Signed a Memorandum of Understanding with MechLine-UK Ltd to commence a plan to introduce Microtox® technologies across several
· Significant progress towards restarting commercial production of QuickChek® SRB kits.
· Customer quotations issued for more than 20,500 QuickChek® SRB kits representing potential sales revenues of approximately
· Successful real-world validation of Metir's proprietary PFAS detection platform with ProDecon.
· FIDCHEM to commence using the PFAS analytical data to develop AI and machine-learning functionality.
· Pathogen Detector Phase 2 to generate Cryptosporidium Optimer® progressing with Aptamer.
Growing Microtox® commercial pipeline
Production of Metir's market-leading Microtox® LX platform continues to increase, enabling the Company to sell units from stock and make units available for trials, with options to lease or purchase units.
During 2026, the Company has issued 144 customer quotations, comprising 53 Microtox® instruments, 30 Microtox® FX instruments and 61 reagent and consumable quotations. To date, 19 Microtox® LX systems have been sold during 2026, with distributors forecasting additional orders during the second half of the year.
The Board believes the continued expansion of the instrument base will support increasing high-margin recurring revenues through reagent sales, consumables and service contracts.
The Company is also planning an upgrade of its unique and world-leading Microtox® Continuous Toxic Monitoring (CTM) platform to work seamlessly with the latest data assimilation systems, SCADA.
UK Marketing Initiative and MechLine-UK Collaboration
Metir exports around 95% of its products and the
MechLine provides engineering, refurbishment and installation services to customers across the
QuickChek® SRB
As announced in the Company's Final Results on
Metir is pleased to report that significant progress has now been made towards the successful development of a replacement antibody. The new antibody is expected to provide a more robust and scalable manufacturing process capable of supporting commercial production to meet demand whilst maintaining the performance characteristics of the existing product.
Run-in production is expected to restart with deliveries in
PFAS Platform Development
Metir has continued to make encouraging progress in the commercial development of its proprietary PFAS ("forever chemicals") detection platform.
Working alongside ProDecon Services, a leading
The programme successfully demonstrated the platform's ability to generate high-quality analytical data in these demanding non-laboratory operating environments, providing further validation of the Company's field-deployable and on-site PFAS detection technology.
The analytical data generated from these evaluations is to be utilised by FIDCHEM as part of the Company's previously announced collaboration to develop AI and machine-learning functionality capable of simplifying PFAS data interpretation and broadening commercial deployment of the platform.
The Board believes the combination of highly sensitive field-deployable PFAS detection with AI-assisted analytics has the potential to provide a unique differentiated commercial offering capable of addressing the growing global demand for rapid environmental monitoring solutions.
Pathogen Detector
Development of Metir's rapid Pathogen Detector capable of detecting Cryptosporidium in water supplies within minutes continues to progress in collaboration with Aptamer Group plc. Following successful completion of the initial feasibility programme announced earlier this year, Phase 2 development remains on track and is focused on demonstrating proof-of-concept performance ahead of commercialisation. The Company continues to expect proof-of-concept data during the second half of 2026 with planned commercial roll-out in H1 2027.
"We continue to be a forward-looking business, making strong progress across our key product development programmes as we build a portfolio of environmental monitoring technologies to widen our revenue base and grow recurring revenue potential. We are also now pursuing strong inroads to the
Our PFAS platform has successfully demonstrated its capabilities under demanding operating conditions, while our collaboration with FIDCHEM is adding AI and machine learning capability that we believe will further differentiate our commercial offering.
We have also made excellent progress towards restarting production of our QuickChek® SRB kits using a re-engineered antibody and we continue to expand Microtox® LX manufacturing to enable the Company to sell units from stock and conduct trials with new customers.
Alongside continued progress with our Pathogen Detector programme in collaboration with Aptamer Group, these developments provide us with confidence in the new commercial opportunities across our portfolio and we look forward to providing further updates as we continue to execute our growth strategy."
- Ends -
Enquiries:
|
Metir plc |
+44 (0) 20 3657 0050 via TPI |
|
|
|
|
SPARK Advisory Partners Limited |
+44 (0)20 3368 3550 |
|
|
|
|
Turner Pope Investments (TPI) Limited Andrew Thacker / |
+44 (0) 20 3657 0050 |
|
Northstar Communications (Investor Relations) |
+44 (0) 113 730 3896 |
About Metir
Metir plc is a leading global provider of several fast-response, mobile and point-of-use water and environmental monitoring technologies. Through its two established trading divisions, Modern Water and Microsaic Systems, a specialist in mobile PFAS monitoring, the Company develops and supplies innovative, easy-to-use solutions that deliver rapid, accurate water and liquids quality results, helping industries, utilities and regulators monitor safety and compliance in real time.
With a strong focus on data-driven insight and field-ready design, Metir's technology supports critical decision-making across sectors, including environmental monitoring, public health and industrial process management.
Headquartered in
For more information, please visit: https://www.metirplc.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE